View Future GrowthLibra Infusions 과거 순이익 실적과거 기준 점검 0/6지난 몇 년간 Libra Infusions 의 실적에 대한 데이터가 부족합니다.핵심 정보n/a순이익 성장률n/a주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률11.00%매출 성장률n/a자기자본이익률n/a순이익률n/a최근 순이익 업데이트30 Jun 2019최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updatesBoard Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (6 non-independent directors). Independent Director Enamul Kabir was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.New Risk • Sep 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported June 2019 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Market cap is less than US$100m (৳1.97b market cap, or US$16.4m).Board Change • Apr 26Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Enamul Kabir was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Upcoming Dividend • Nov 06Upcoming dividend of ৳3.00 per share at 0.2% yieldEligible shareholders must have bought the stock before 13 November 2023. Payment date: 01 January 2024. Trailing yield: 0.2%. Lower than top quartile of Bangladeshi dividend payers (3.2%). Lower than average of industry peers (2.5%).New Risk • Oct 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Bangladeshi stocks, typically moving 7.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2019 fiscal period end). Share price has been highly volatile over the past 3 months (7.9% average weekly change). Minor Risk Market cap is less than US$100m (৳2.54b market cap, or US$23.0m).공고 • Oct 24Libra Infusions Limited, Annual General Meeting, Nov 30, 2023Libra Infusions Limited, Annual General Meeting, Nov 30, 2023, at 11:00 Bangladesh Standard Time.Board Change • Nov 21Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Enamul Kabir was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Upcoming Dividend • Aug 07Upcoming dividend of ৳0.50 per shareEligible shareholders must have bought the stock before 14 August 2022. Payment date: 20 September 2022. Trailing yield: 0.1%. Lower than top quartile of Bangladeshi dividend payers (3.7%). Lower than average of industry peers (1.9%).공고 • Jul 25Libra Infusions Limited Recommends Cash DividendThe Board of Directors of Libra Infusions Limited has recommended 5% cash dividend only for General Shareholders other than Sponsors and Directors for the year ended June 30, 2020.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Upcoming Dividend • Apr 27Upcoming dividend of ৳0.50 per shareEligible shareholders must have bought the stock before 04 May 2021. Payment date: 23 June 2021. Trailing yield: 0.4%. Lower than top quartile of Bangladeshi dividend payers (3.5%). Lower than average of industry peers (1.5%).Is New 90 Day High Low • Mar 01New 90-day high: ৳685The company is up 17% from its price of ৳586 on 01 December 2020. The Bangladeshi market is up 15% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also up 17% over the same period.Is New 90 Day High Low • Feb 01New 90-day low: ৳582The company is down 11% from its price of ৳657 on 03 November 2020. The Bangladeshi market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 21% over the same period.Is New 90 Day High Low • Dec 21New 90-day high: ৳677The company is up 1.0% from its price of ৳670 on 22 September 2020. The Bangladeshi market is also up 1.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Pharmaceuticals industry, which is up 5.0% over the same period.매출 및 비용 세부 내역Libra Infusions가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DSE:LIBRAINFU 매출, 비용 및 순이익 (BDT Millions)날짜매출순이익일반관리비연구개발비30 Jun 19197256030 Jun 18191661031 Mar 18191-1660031 Dec 17241562030 Sep 17245562030 Jun 17244663031 Mar 17290567031 Dec 16259363030 Sep 16231860030 Jun 16238657031 Mar 16232962031 Dec 15247661030 Sep 15272-4590양질의 수익: LIBRAINFU가 고품질 수익을 갖고 있는지 판단하기에는 데이터가 부족합니다.이익 마진 증가: 지난 1년 동안 LIBRAINFU의 이익률이 개선되었는지 판단하기에 데이터가 부족합니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 LIBRAINFU의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: LIBRAINFU의 지난해 수익 성장률을 5년 평균과 비교하기에 데이터가 부족합니다.수익 대 산업: LIBRAINFU의 지난 해 수익 증가율이 Pharmaceuticals 업계 평균을 상회했는지 판단하기에 데이터가 부족합니다.자기자본이익률높은 ROE: LIBRAINFU는 현재 수익성이 없으므로 자본 수익률이 음수(0%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/22 04:41종가2026/07/22 00:00수익2019/06/30연간 수익2019/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Libra Infusions Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (6 non-independent directors). Independent Director Enamul Kabir was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
New Risk • Sep 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported June 2019 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Market cap is less than US$100m (৳1.97b market cap, or US$16.4m).
Board Change • Apr 26Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Enamul Kabir was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • Nov 06Upcoming dividend of ৳3.00 per share at 0.2% yieldEligible shareholders must have bought the stock before 13 November 2023. Payment date: 01 January 2024. Trailing yield: 0.2%. Lower than top quartile of Bangladeshi dividend payers (3.2%). Lower than average of industry peers (2.5%).
New Risk • Oct 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Bangladeshi stocks, typically moving 7.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2019 fiscal period end). Share price has been highly volatile over the past 3 months (7.9% average weekly change). Minor Risk Market cap is less than US$100m (৳2.54b market cap, or US$23.0m).
공고 • Oct 24Libra Infusions Limited, Annual General Meeting, Nov 30, 2023Libra Infusions Limited, Annual General Meeting, Nov 30, 2023, at 11:00 Bangladesh Standard Time.
Board Change • Nov 21Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Enamul Kabir was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • Aug 07Upcoming dividend of ৳0.50 per shareEligible shareholders must have bought the stock before 14 August 2022. Payment date: 20 September 2022. Trailing yield: 0.1%. Lower than top quartile of Bangladeshi dividend payers (3.7%). Lower than average of industry peers (1.9%).
공고 • Jul 25Libra Infusions Limited Recommends Cash DividendThe Board of Directors of Libra Infusions Limited has recommended 5% cash dividend only for General Shareholders other than Sponsors and Directors for the year ended June 30, 2020.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Upcoming Dividend • Apr 27Upcoming dividend of ৳0.50 per shareEligible shareholders must have bought the stock before 04 May 2021. Payment date: 23 June 2021. Trailing yield: 0.4%. Lower than top quartile of Bangladeshi dividend payers (3.5%). Lower than average of industry peers (1.5%).
Is New 90 Day High Low • Mar 01New 90-day high: ৳685The company is up 17% from its price of ৳586 on 01 December 2020. The Bangladeshi market is up 15% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also up 17% over the same period.
Is New 90 Day High Low • Feb 01New 90-day low: ৳582The company is down 11% from its price of ৳657 on 03 November 2020. The Bangladeshi market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 21% over the same period.
Is New 90 Day High Low • Dec 21New 90-day high: ৳677The company is up 1.0% from its price of ৳670 on 22 September 2020. The Bangladeshi market is also up 1.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Pharmaceuticals industry, which is up 5.0% over the same period.